Amphastar Pharmaceuticals Receives FDA Approval for Teriparatide Injection
Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the Company's Abbreviated New Drug Application for teriparatide injection, USP 560 mcg/2.24mL single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO.
